SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

20.9% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 84.7% of Exelixis shares are held by institutional investors. 42.0% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares SAB Biotherapeutics and Exelixis' gross revenue, earnings per share (EPS) and valuation.

Risk & Volatility

SAB Biotherapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for SAB Biotherapeutics and Exelixis, as provided by MarketBeat.com.

SAB Biotherapeutics presently has a consensus target price of $3.67, suggesting a potential upside of 439.69%. Exelixis has a consensus target price of $27.58, suggesting a potential upside of 60.55%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Exelixis.

Profitability

This table compares SAB Biotherapeutics and Exelixis' net margins, return on equity and return on assets.

Summary

Exelixis beats SAB Biotherapeutics on 8 of the 12 factors compared between the two stocks.

About SAB Biotherapeutics

(Get Rating)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

About Exelixis

(Get Rating)

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.